Moderna Inc. (MRNA) shares rose as much as 14% on Friday, May 8, 2026.
The company announced early-stage development of a hantavirus vaccine following a cruise ship outbreak. This research involves the U.S. Army Medical Research Institute of Infectious Diseases and Korea University College of Medicine. Moderna confirmed the collaboration began before the recent outbreak.
The New England Journal of Medicine published positive Phase 3 results for the mRNA-1010 seasonal flu vaccine. The trial data showed the vaccine outperformed standard-dose shots in older adults.